Contact
Please use this form to send email to PR contact of this press release:
QuidelOrtho (QDEL) Securities Fraud Class Action Filed After QDEL Reports Disastrous Q4 2023 Results, Terminates CEO, Withdraws FDA Submission - Hagens Berman
TO: